Sign In
Buy PTN
$11.77
+0.0500 (+0.427%)
At Close: Jun 22, 2026
Palatin to Begin Trading on Nasdaq Stock Exchange
04:00pm, Monday, 18'th May 2026
PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development of novel therapeutics targeting the
Palatin Technologies, Inc. (PTN) Q3 2026 Earnings Call Transcript
03:00pm, Wednesday, 13'th May 2026
Palatin Technologies, Inc. (PTN) Q3 2026 Earnings Call Transcript
Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
07:30am, Wednesday, 13'th May 2026
Advancing MC4R-based obesity programs for rare obesity disorders with a focus on improved tolerability and long-term use, and key IND submissions targeted in calendar 2026 and 2027 Programs target rar
Palatin Technologies Q2 Earnings Call Highlights
04:07am, Thursday, 19'th Feb 2026
Palatin Technologies (NYSEAMERICAN:PTN) executives highlighted recent financing activity, progress in the company's melanocortin-4 receptor (MC4R)-based obesity pipeline, and updated financial results
Palatin Technologies, Inc. (PTN) Q2 2026 Earnings Call Transcript
01:34pm, Tuesday, 17'th Feb 2026
Palatin Technologies, Inc. (PTN) Q2 2026 Earnings Call Transcript
Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
07:30am, Tuesday, 17'th Feb 2026
Advancing differentiated MC4R-based obesity programs into clinical development Melanocortin-based obesity therapies targeting rare MC4R pathway disorders with a primary focus on hypothalamic obesity a
Why Are Palatin Technologies (PTN) Shares Spiking After-Hours?
02:20am, Thursday, 11'th Dec 2025
Palatin Technologies shares rose in after-hours trading as Janus Henderson Group and its subsidiary reported shared ownership of the company's stock.
Pre-Market Stock Futures: The futures are trading higher on Wednesday after a stellar day across Wall Street on Tuesday. All of the major indices finished the day higher, with the technology-heavy NAS
Palatin Technologies, Inc. (PTN) Q1 2026 Earnings Call Transcript
03:41pm, Thursday, 13'th Nov 2025
Palatin Technologies, Inc. (OTC:PTN) Q1 2026 Earnings Call November 13, 2025 11:00 AM EST Company Participants Carl Spana - Co-Founder, President, CEO & Director Steve Wills - CFO, COO, Executive VP,
Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
07:30am, Thursday, 13'th Nov 2025
Significant progress on multiple fronts – obesity pipeline advancing towards the clinic, out-licensing collaboration, strengthened balance sheet, and reinstatement of NYSE American trading Melanocor
Trading of Palatin's common shares resumed trading on NYSE today, November 12, 2025, under the symbol "PTN" PRINCETON, N.J. , Nov. 12, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: P
Palatin Presents Data at ObesityWeek® 2025 Highlighting Promise of Melanocortin-Based Therapies for Obesity
08:00am, Thursday, 06'th Nov 2025
Oral MC4R agonist PL7737 demonstrated robust weight loss, safety, and high oral bioavailability in preclinical models Clinical data supports co-administration of an MC4R agonist with tirzepatide as a
Palatin Technologies Announces Pricing of Upsized $15.8 Million Public Offering
07:30am, Thursday, 06'th Nov 2025
$15.8 million at closing with up to an additional $15.8 million upon the cash exercise of the milestone related warrants Regains compliance with NYSE American exchange listing standard - trading of Pa
Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim
07:30am, Monday, 22'nd Sep 2025
Collaboration focused on developing potential first-in-class melanocortin receptor targeted treatment for patients with diabetic retinopathy, including diabetic macular edema PRINCETON, N.J. , Sept. 2
Boehringer and Palatin Technologies team up to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases
